Close

Quintiles and London Genetics Alliance T0 Enchance Drug Discovery and Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories said, In the New Health, bio pharmaceutical companies are under relentless pressure to replenish their product pipelines and deliver safer, more effective medicines to patients in need. Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world.

Dominique Kleyn, CEO of London Genetics said, Our expertise in pharmacogenetic strategy development combined with Quintiles’ expertise and infrastructure in biomarker development gives biopharma companies a powerful ally in harnessing the value of genomic data for drug development. Ultimately, our alliance will support biopharma in their interactions with academic partners and in the development of personalized medicines.

 

Latest stories

Related stories

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back